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Introduction
Pharmacobezoars are an uncommon but potentially prob-
lematic manifestation of drug overdose. Diagnosed radio-
graphically, endoscopically, intraoperatively, or postmortem,
a bezoar is a mass of any form of unabsorbed material within
the gastrointestinal tract. When they occur, they tend to form
at anatomic strictures at any point between the esophagus
and the rectum. They commonly occur in patients with prior
abdominal surgery or altered GI motility. Besides obstructive
and ischemic complications when impacted, pharmacobe-
zoars can also cause prolonged toxicologic effects due to the
retained drug mass.
Venlafaxine is a bicyclic phenylethylamine antidepres-
sant that inhibits serotonin, norepinephrine, and dopamine
reuptake in the CNS. Morbidity and mortality from
venlafaxine overdose are typically from seizures and
cardiovascular toxicity. We describe a novel case of
massive overdose of extended-release (ER) venlafaxine
leading to obstructive pharmacobezoar formation at the
ileocecal junction, with consequent bowel ischemia and
necrosis requiring emergent hemicolectomy.
Case Report
A 28-year-old woman with a history of major depression
was brought to the emergency room at midnight, 1 hour
following an intentional overdose of her venlafaxine
medication. Her parents found empty bottles of venlafaxine
ER 37.5 mg tablets (300 count) and venlafaxine ER 150 mg
tablets (100 count) filled 1 and 13 weeks prior to
presentation, respectively. On arrival to the emergency
department (ED), the patient was asymptomatic. Initial vital
signs included a temperature of 36.8°C, blood pressure of
137/82 mmHg, heart rate of 78 beats/min, and respiratory
rate of 18 breaths/min. Among her normal physical
examination findings was a nontender abdomen with active
bowel sounds. Her initial laboratory work-up, including a
complete blood count and basic metabolic panel, was
unremarkable. Acetaminophen and aspirin levels were
negative.
The regional poison control center was contacted. Based
on the patient’s prescription fill dates, the specialist in
poison information calculated a maximum probable dose of
10 g. To achieve a 10:1 activated charcoal to drug ratio,
100 g of activated charcoal was recommended, which the
patient tolerated well. Since there was concern for drug-
induced seizures, further gastrointestinal decontamination
measures, including whole bowel irrigation, were thought
to incur too much risk of aspiration.
While in the ED, by 5 h after ingestion, the patient had
developed tachycardia to a heart rate of 130 beats/min and
tremulousness that was treated with a total of lorazepam
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control center, the patient was admitted for observation for
cardiac arrythmias and seizures.
Twenty-eight hours after ingestion, the patient began
complaining of sharp abdominal pain at the right lower
quadrant. At this time, she also had mild anorexia and one
episode of loose liquid stool with no bright red blood per
rectum. The patient’s vital signs included a temperature of
37.2°C, blood pressure of 130/95 mmHg, heart rate of 112
beats/min, and respiratory rate of 20 breaths/min. On
physical examination, the patient had tenderness suprapubi-
cally and diffusely across the right lower quadrant.
Although she exhibited mild voluntary guarding, no
rebound was noted. The patient also had active bowel
sounds. Repeat laboratory testing was significant for an
elevated white blood cell count of 18.8×10
3 cells/μL.
Otherwise, a repeat basic chemistry panel was normal as
well as lactate which was measured to be 1.3 mmol/L. A
CT scan of the abdomen and pelvis with oral and IV
contrasts was obtained, which revealed “extensive scallop-
ing of the wall of the entire right colon with air in the wall”
and a large mass of tablets in the cecum (Figs. 1 and 2). The
patient was emergently taken to the operating room for an
exploratory laparotomy, given concern for suspected right
bowel ischemia.
On laparotomy, surgeons found a thick-walled and
edematous right colon with surrounding cloudy ascites
and inflamed edematous tissue. Beyond the hepatic flexure,
the colon was completely normal on inspection and
palpation, as were the small bowel, uterus, gallbladder,
and liver. A right colectomy with a primary hand-sewn
anastomosis was performed. Following removal, the spec-
imen was bivalved, revealing a loose conglomeration of
over 80 white, round tablets with central umbilication in the
cecum with surrounding necrotic cecal mucosa (Fig. 3).
The tablets were identified as venlafaxine ER 37.5-mg and
150-mg tablets (Upstate Pharma, LLC) by visual inspec-
tion, correlation to the patient’s pharmaceutical distribution
record, and comparison to published images [1]. No
activated charcoal was visualized. Pathologic inspection of
the specimen revealed an area of green-to-black ulcerated
necrosis on the cecum and ascending colon measuring 13.7
by 9.2 cm with surrounding edematous mucosa. No colonic
masses or perforations were noted.
During the remainder of her hospital stay, the patient
recovered well with normalization of her vital signs, return
of bowel function, and sufficient pain control. After a
psychiatric evaluation, she was discharged home on
postoperative day 4 with intensive outpatient psychiatric
follow-up.
Fig. 1 Axial view of abdomen and pelvis using CT demonstrating
tablet bezoar with associated bowel pneumatosis
Fig. 2 Coronal reconstruction of a CTscan of the abdomen and pelvis
demonstrating tablet bezoar at the ileocecal junction
Fig. 3 Excised right colon and cecum demonstrating tablet bezoar
with associated necrotic cecal mucosa
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Pharmacobezoars are potentially deadly. On occasion, they
can cause bowel obstruction with resultant ischemia [2–4].
Additionally, these pharmaceutical concretions can cause
sustained toxic effects through continued release of active
ingredients.
Historically, medications causing pharmacobezoar for-
mation include aspirin, antacids, iron, bulk laxatives, and
ER products such as nifedipine and theophylline. The
etiology of bezoar formation is multifactorial. Patients
who have alterations in gastrointestinal anatomy or
dysmotility are at risk. Medications may form bezoars
when they modify gastrointestinal function. Anticholi-
nergics and opioids slow gut motility. In overdose,
aspirin is believed to cause pylorospasm, delaying gastric
emptying. Pharmaceuticals, including extended- or
sustained-release (SR) products, with significant unab-
sorbable components, are prone to bezoar formation. For
example, nifedipine SR products consist of an insoluble
cellulose acetate shell that is excreted whole [5]. Finally,
massive tablet ingestions, regardless of formulation, have
caused pharmacobezoars [6, 7].
Our patient developed a venlafaxine ER pharmacobezoar.
Two factors from the patient’s ingestion history, the massive
quantity of tablets and the venlafaxine ER product’s
(Upstate Pharma, LLC) insoluble cellulose acetate shell,
increased the risk of pharmacobezoar formation.
An unusual aspect of this case is the absence of overt
clinical or radiographic signs of bowel obstruction
despite development of bowel ischemia from a pharma-
cobezoar. There are two potential explanations. First, the
patient likely had a partial or evolving bowel obstruc-
tion. Some degree of obstruction certainly existed for a
bezoar to form at the anatomic stricture of the ileocecal
junction. Additionally, the patient’s concomitant loose
stool while developing abdominal pain is consistent
with encopresis. It may be that diagnosis and interven-
tion occurred prior to complete bowel obstruction. A
second explanation is that local drug effects contributed
to the development of tissue ischemia. Theoretically,
bowel wall immediately adjacent to a pharmacobezoar
w o u l db ee x p o s e dt or e l a t i v e l yh i g hd r u gc o n c e n t r a -
tions. Norepinephrine reuptake inhibition is already
known to contribute to systemic toxicity from venlafax-
ine. High, local tissue concentrations of venlafaxine
might cause focal alpha-adrenergic vasoconstriction.
Such vasoconstriction could further compromise perfu-
sion to tissue already under mechanical stress from the
bezoar, worsening ischemia. In this case, we believe
that our patient’s bowel ischemia was primarily due to
an evolving mechanical bowel obstruction, but possibly
exacerbated by localized drug toxicity.
There have been only two case reports of venlafaxine
overdose with gastrointestinal manifestations. First, a 47-
y e a r - o l df e m a l ew h oi n g e s t e da ne s t i m a t e d1 5go f
venlafaxine SR formed a gastric bezoar. The bezoar was
diagnosed when high gastric residuals through the first
5 days of her hospital course warranted endoscopic
investigation. The patient ultimately suffered devastat-
ing cerebrovascular infarcts from multiple seizures and
hypoxia from respiratory arrest, aspiration pneumonitis,
and acute respiratory distress syndrome [8]. Second, a
39-year-old female who ingested an estimated 30 g of
venlafaxine capsules suffered from bowel ischemia and
perforation due to persistent, refractory hypotension. On
day 14 of her hospital course, bowel ischemia and
perforation were diagnosed by rapid abdominal disten-
tion and intraperitoneal air visualized radiographically.
No bezoar was found on emergent laparotomy [9]. In
juxtaposition to these two cases, our patient was
normotensive, although tachycardic, throughout her
hospitalization and developed bowel ischemia from a
venlafaxine pharmacobezoar diagnosed by exploratory
laparotomy.
Effective screening for bezoars is difficult. Pharma-
ceuticals are inconsistently radio-opaque, so simple
screening techniques such as abdominal X-rays would
likely have poor sensitivity. Given the rarity of pharma-
cobezoars, it is difficult to justify the expense, resource
utilization, and radiation exposure for routine endoscopy
or CT scan in patients who exhibit no abdominal signs or
symptoms. Therefore, we believe that diagnostic studies
should continue to be reserved for patients with abdom-
inal signs and symptoms.
Therapy for pharmacobezoars are numerous, but
controversial. They include multiple-dose activated char-
coal (MDAC), whole bowel irrigation (WBI), endoscopic
removal, and surgical removal. For one, repeated doses
of activated charcoal should absorb drug continually
released from a retained pharmacobezoar, limiting further
drug toxicity. However, since activated charcoal itself is
unabsorbable, MDAC risks exacerbation of an existing
pharmacobezoar or creation of a new one [2]. Another
option, WBI has been utilized with inconsistent success to
hasten passage or disruption of a pharmacobezoar [7–8]. If
initiated early after a massive ingestion, WBI may prevent
bezoar formation altogether. However, these potential
benefits must be weighed against potential aspiration
risks. And, in the setting of a complete bowel obstruction
or ileus, bowel distention with liters of fluid is dangerous.
Endoscopy is another potential intervention. Numerous
successful reports exist for both gastric and colonic
bezoars. As well, this method is not always successful
and procedural complications, such as upper GI bleeding,
have been reported [6].
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surgical removal of pharmacobezoars has been performed
under select circumstances. Typically, intraoperative re-
moval has been performed when a pharmacobezoar has
caused frank or progressive bowel obstruction or has been
refractory to more conservative treatment [10, 11]. Rarely, a
pharmacobezoar causes bowel ischemia, necessitating
emergent surgical intervention [2–4].
We describe a novel case of a venlafaxine ER bezoar
causing intestinal ischemia necessitating emergent hemicolec-
tomy. This case illustrates the need for clinical suspicion for
pharmacobezoar formation in the setting of a massive
extended-release pharmaceutical ingestion. In these circum-
stances,patientswhohaveactivebowelsoundsandlowriskfor
aspiration should be considered for multiple doses of activated
charcoal and/or whole bowel irrigation. These therapies may
mitigate prolonged toxicologic drug effects and prevent
formation or hasten passage of a pharmacobezoar, respectively.
Diagnostic endoscopy or CT scan should be reserved for
patients exhibiting abdominal signs and symptoms.
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